Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Aptamer Trading Update this AM:
RNS Number : 5008Y
Aptamer Group PLC
05 May 2023
Revenue for the ten months ended 30 April 2023 was approximately Ā£1.4m (unaudited) as the existing pipeline of new business has taken longer than expected to convert, especially licensing and royalty-based contracts, against a backdrop of continuing market headwinds.
The Group now expects full year revenues to be materially below FY2022. The sales pipeline remains healthy across both fee-for-service and licensing, and while the Group expects some of this to be recognised as revenue in the current financial year, the majority, if converted, will fall into the next financial year.
https://www.londonstockexchange.com/news-article/APTA/trading-update/15944660
Well they aren't indicating PD isn't happening so that's good... (even if maybe don't be holding your breath while waiting). Year end 30 June, so their outlook still allows for a good six months to end '23 for DVRG.
T Rat,
I think the Mkt has moved on from PD, for the time being at least - IMO;
Mkt wants to hear about the cash flow, settlement plan/s (eg with MSYS) and how current and future contracts will be executed, given the dire WCap situation;
Looking at the past 2-3 days trading, I'd assume that the Co will soon announce positive developments on these fronts, again IMO.
DYOR, GLA!
A quick reminder of where company should be at...
From Investor Meet Company:
DVRG AGM
20th Jul 2022 at 12:00pm BST
Q8: What time scale do you see you can get the lowest cost version of Microtox PD, and roughly where do you aspire for the lowest cost to be?
The MicrotoxPD unit is in a constant evolution to reduce in size and achieve multiplex (range of pathogens on a single chip) and it is likely that this will continue over the duration of the 2.8m Euro project of development, partly paid for by Enterprise Ireland and the grant of 750,000. This is about half way through a 24 month project.
##
##
So that project should be reaching a conclusion shortly (or for those that prefer, soon). Especially given the reckless abandon of spending with MSYS... yes? To date we've seen nothing for money spent.
Same source:
Q41: When will a product listing for Microtox PD be added to Modern Water website?
We still classify them as under development, and will add them when we have the full array of consumables, and pathogens to be detected as part of a catalogue. It is important to understand that we are rolling these units out as we continue to tweak and develop and miniaturise them dynamically
##
##
Between then and now still no product listing. Likewise nothing for MicroTrace PDV7000...
Delays to orders that have caused current difficulties can be laid at the door of those outside the company. The delivery of project can not.
Time draws near to demonstrate capabilities...
I fear that the reality on product development etc will be nowhere near the hyperbole from our ex CEO.
It is pretty clear that the posts from ex-employees suggesting that the some of the developments were little more than a figment of an over active imagination were pretty much on the money unfortunately.
An update on the cash situation would be most welcome.
Muggins, which posts are you referring to and where can I see them?
I think you will find G Woods was the best example for negative imformation .
Given thread title I'll note this here:
Aptamer Group plc (AIM: APTA), the developer of novel OptimerĀ® binders to enable innovation in the life sciences industry, today announces that Dr. Arron Tolley has left his position as Chief Executive Officer and Board Director, with immediate effect. He will leave his employment with the Group after a period of garden leave. As a consequence, the Chairman of the Board, Dr. Ian Gilham, will assume the role of interim Executive Chairman, and current Chief Financial Officer, Dr. Rob Quinn, will now also assume the role of interim CEO. A search for a full-time CEO will begin immediately.
https://www.londonstockexchange.com/news-article/APTA/aptamer-group-directorate-change/15949476
And despite the thread title I'll note this here:
Senior author of the study Jun Ye, a professor of physics at the University of Colorado Boulder, said the potential for the technology was "endless".
"There is a real, foreseeable future in which you could go to the doctor and have your breath measured along with your height and weight," he said.
"Or you could blow into a mouthpiece integrated into your phone and get information about your health in real-time."
https://news.sky.com/story/breathalyser-can-sniff-out-diseases-in-real-time-and-could-attach-to-your-phone-12877671
With their breathalyser currently being the size of a large table the obvious question becomes who will be first to market...
'course we can't even get a website update (and if that is too much to ask then at least a redirect so the out of date website is no longer available...):
https://www.microtoxbt.com/
Perhaps whoever is now responsible could take the thirty seconds to sort things (and another thirty seconds to correct company name on Twitter...):
and was responsible for all marketing and PR communications for all brands within the portfolio.
https://ie.linkedin.com/in/niamh-o-kennedy-33b4957
If that attention to detail impressed Webbiz I'm not sure what to say...